Table 5.

Adverse events

System	Adverse event: no. of patients (%)
Hematologic	Neutropenia Grade 4: 1 (7%) Grade 3: 3 (23%) Grade 2: 1 (7%)
Infectious	Upper respiratory tract infection: 5 (38%) Sinusitis: 2 (15%) Influenza: 1 (7%)
Rheumatologic	Gout: 2 (15%) Elevated creatine phosphokinase, grade 1: 3 (23%)
Neurologic	Dysesthesias (hands and/or feet), grade 1: 3 (23%) Tremor, grade 1: 1 (7%) Headache: 3 (23%)
Gastrointestinal	Hyperbilirubinemia, grade 1: 3 (23%) Other liver test abnormalities (alanine aminotransferase), grade 1: 2 (15%) Dyspepsia: 2 (15%)
Cardiovascular	New-onset hypertension requiring therapy: 2 (15%) Worsening of hypertension requiring additional therapy: 5 (39%)
Metabolic	Hyperkalemia, grade 2: 1 (7%); grade 1: 2 (15%) Hypomagnesemia, grade 1: 3 (23%) Hyperglycemia: 1 (7%)
Other	Increased hair growth or coarser hair: 4 (30%) Gingival hyperplasia: 1 (7%)

Grading based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.